Drug Dealin

• Ep 3: Rise of the Phoenix | Sujal Shah & CymaBay Therapeutics

  A conversation with biotech leader, Sujal Shah, former CEO of CymaBay Therapeutics about his company's story arc, leadership, resilience, and building a biotech company in the face of adversity. Questions?: [email protected] Follow us on X: https://x.com/DrugDealinPodConnect with Shivu: https://linktr.ee/shivusharmaCheck out Big Pharma Sharma: https://bigpharmasharma.substack.com/ Connect with Kenny: https://www.linkedin.com/in/kennylalwani/ 00:00 Introduction to Biotech Leadership 03:00 Sujal Shah's Journey in Biotech05:46 Leadership Philosophy and Team Dynamics 09:13 Navigating Challenges at CymaBay 11:48 The Development of seladelpar 15:07 Strategic Decisions in Drug Development 17:58 Clinical Trials and Regulatory Interactions 20:50 The NASH Study and Its Implications 47:10 Navigating Drug Development Challenges 49:07 The Patient-Centric Approach in Drug Development 51:56 Facing Clinical Setbacks and Organizational Resilience 53:36 Unexpected Findings and Immediate Reactions 01:00:27 The Emotional Toll of Drug Development 01:05:08 Rebuilding Purpose and Finding Answers 01:19:52 Patient Advocacy and Support During Crisis 01:23:30 Uncovering the Truth: The Role of Independent Panels 01:33:59 Independent Review and Safety Assurance 01:36:50 Leadership Challenges and Stakeholder Management 01:40:12 Resilience in Adversity 01:43:51 Turning Point: Stock Recovery and Investor Relations 01:47:07 Skepticism and Ongoing Challenges 01:55:00 Data Presentation and Competitive Landscape 02:01:11 Building a Robust Evidence Package 02:04:53 Reflections on Leadership and Future Aspirations

  --------  

  2:20:49
• Ep. 2: Predictions for Biopharma in 2025

  Kenny and Shivu each cook up three predictions for Biopharma in 2025NOTE: This episode was recorded on January 10th, 2025Have feedback for us? Leave a comment or email us at [email protected]

  --------  

  57:57
• Ep. 1: Do Pharma Companies Avoid Cures?

  In this episode, we unpack, examine, and debunk the public perception that drug companies intentionally do not pursue curative therapies, because it is financially less beneficial to them. We speak from our own experience working on curative therapies in Oncology and HCV, discuss how difficult it is to develop cures, the implications of curing a disease for drug companies, and how the industry can do a better job fostering trust with patients. Have feedback for us? Feel free to leave a comment or send us an email at [email protected]

  --------  

  1:13:48
• Ep. 0: Welcome to the Drug Dealin' Podcast!

  What is Drug Dealin' going to be about? How are the Drug Dealin' hosts and should you listen to us? What type of content can you expect from this show?

  --------  

  21:49

Altri podcast di Scienze

Podcast di tendenza in Scienze

Su Drug Dealin